Drug intelligence / Profile preview

NBT-102

Development stage: Preclinical
Lead developer: Nanobots Therapeutics
Modality: Nanoparticles → Drug Delivery Systems

Overview

NBT-102 is a therapeutic nanorobot candidate being developed by Nanobots Therapeutics for the treatment of colorectal cancer. It is built upon the proprietary MotionTx technology platform, which utilizes biocompatible nanorobots capable of autonomous movement using the body's natural resources. This technology is designed to overcome biological barriers that typically limit drug delivery, enabling superior tissue penetration and enhanced accumulation within target cancer cells. While specific molecular targets and detailed clinical phases have not been publicly disclosed, NBT-102 represents a novel class of therapeutics aimed at improving the efficacy of cancer treatments through active transport mechanisms.

Beyond the preview

Go deeper on NBT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBT-102.

Explore the full profile